Journal
ANNUAL REVIEW OF MEDICINE
Volume 56, Issue -, Pages 29-44Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev.med.56.082103.104727
Keywords
lymphoma; Epstein-Bair virus; solid organ transplant; hematopoietic stem cell transplant; immunotherapy
Categories
Funding
- NCI NIH HHS [P01 CA094237, R01 CA94237, CA61384] Funding Source: Medline
- NCRR NIH HHS [RR00188] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [R01CA061384, U01CA061384, P01CA094237] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication after hematopoietic stem cell or solid organ transplantation. The majority of PTLD is of B-cell origin and associated with Epstein-Barr virus (EBV). During the past decade progress has been made in better understanding the pathogenesis of PTLD, and early detection strategies, such as serial measurement of EBV-DNA load in peripheral blood samples, have assisted in the identification of high-risk patients. In addition, novel immunotherapies have been developed, including the use of monoclonal antibodies and adoptive transfer of EBV-specific T cells. Despite these advances, it remains a major challenge to define indications for preemptive therapies for PTLD and to integrate novel therapeutic approaches with conventional therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available